# To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

> **NCT03331523** · PHASE3 · COMPLETED · sponsor: **Glenmark Pharmaceuticals Ltd. India** · enrollment: 643 (actual)

## Conditions studied

- Scalp Psoriasis

## Interventions

- **DRUG:** Calcipotriene/Betamethasone Dipropionate
- **DRUG:** Taclonex®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03331523
- **Lead sponsor:** Glenmark Pharmaceuticals Ltd. India
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-20
- **Primary completion:** 2018-10-25
- **Final completion:** 2018-10-25
- **Target enrollment:** 643 (ACTUAL)
- **Last updated:** 2018-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331523, "To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03331523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*